801
|
Meng Z, Liu L, Shen Y, Yang P, Cohen L, Huo Y, Zhao Q, Ng CS, Chang DZ, Garrett CR. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
802
|
Brewster AM, Parker PA, Bedrosian I, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
803
|
Sun J, Chen J, Yao Y, Zhang R, Zheng Y, Liu L, Zhang L, Shen Y, Lu H. Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients. Int J STD AIDS 2011; 21:810-3. [PMID: 21297088 DOI: 10.1258/ijsa.2010.010114] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To assess the relationship between mean efavirenz (EFV) plasma concentration and clinical effect during the first 48 weeks of combination antiretroviral therapy (cART), the baseline CD4 cell count was recorded and plasma EFV concentration and CD4 cell count were measured every 12 weeks. HIV-RNA viral load was determined in the 48th week of cART. In total, 42 subjects were recruited and grouped according to their mean concentration of EFV during the study period: groups A, B and C with EFV concentrations (mean) <2 mg/L (1.8 mg/L), 2-4 mg/L (2.9 mg/L) and >4 mg/L (5.5 mg/L), respectively. The CD4 cell counts in group C increased more quickly than in groups B and A, although this was not statistically significant (211 ± 176/μL versus 151 ± 145/μL and 172 ± 105/μL, respectively; P = 0.799). Groups B and C had higher rates of HIV viral load suppression than group A (P = 0.017). For treatment-naïve Chinese HIV-infected patients, EFV plasma concentrations above 2 mg/L appear to suppress HIV replication more effectively than concentrations below 2 mg/L.
Collapse
|
804
|
Miao F, Sun H, Pan N, Shen Y, Xie W, Zhang J. Two novel HLA class I alleles, HLA-B*40:122 and HLA-B*40:127. ACTA ACUST UNITED AC 2011; 77:156-7. [PMID: 21214529 DOI: 10.1111/j.1399-0039.2010.01586.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The new alleles human leukocyte antigen (HLA)-B*40:122 and HLA-B*40:127 differs from B*40:02:01 and B*40:06:01:01 by a single nucleotide, respectively.
Collapse
|
805
|
Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-Struckmeier S, Caras S, Whitcomb DC. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther 2011; 33:1152-61. [PMID: 21418260 DOI: 10.1111/j.1365-2036.2011.04631.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM To assess the long-term safety and efficacy of pancrelipase (pancreatin) delayed-release capsules (Creon) in this population. METHODS This was a 6-month, open-label extension of a 7-day, double-blind, placebo-controlled study enrolling patients ≥18 years old with confirmed EPI due to CP or PS who were previously receiving PERT. Patients received individualised pancrelipase doses as directed by investigators (administered as Creon 24 000-lipase unit capsules). RESULTS Overall, 48 of 51 patients completed the open-label phase; one withdrew due to the unrelated treatment-emergent adverse event (TEAE) of cutaneous burns and two were lost to follow-up. The mean age was 50.9 years, 70.6% of patients were male, 76.5% had CP and 23.5% had undergone PS. The mean±s.d. pancrelipase dose was 186960±74640 lipase units/day. TEAEs were reported by 22 patients (43.1%) overall. Only four patients (7.8%) had TEAEs that were considered treatment related. From double-blind phase baseline to end of the open-label period, subjects achieved a mean±s.d. body weight increase of 2.7±3.4 kg (P<0.0001) and change in daily stool frequency of -1.0±1.3 (P<0.001). Improvements in abdominal pain, flatulence and stool consistency were observed. CONCLUSIONS Pancrelipase was well tolerated over 6 months and resulted in statistically significant weight gain and reduced stool frequency in patients with EPI due to CP or PS previously managed with standard PERT.
Collapse
|
806
|
Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-Struckmeier S, Caras S, Whitcomb DC. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther 2011. [PMID: 21418260 DOI: 10.1111/j.1365-2 036.2011.04631.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM To assess the long-term safety and efficacy of pancrelipase (pancreatin) delayed-release capsules (Creon) in this population. METHODS This was a 6-month, open-label extension of a 7-day, double-blind, placebo-controlled study enrolling patients ≥18 years old with confirmed EPI due to CP or PS who were previously receiving PERT. Patients received individualised pancrelipase doses as directed by investigators (administered as Creon 24 000-lipase unit capsules). RESULTS Overall, 48 of 51 patients completed the open-label phase; one withdrew due to the unrelated treatment-emergent adverse event (TEAE) of cutaneous burns and two were lost to follow-up. The mean age was 50.9 years, 70.6% of patients were male, 76.5% had CP and 23.5% had undergone PS. The mean±s.d. pancrelipase dose was 186960±74640 lipase units/day. TEAEs were reported by 22 patients (43.1%) overall. Only four patients (7.8%) had TEAEs that were considered treatment related. From double-blind phase baseline to end of the open-label period, subjects achieved a mean±s.d. body weight increase of 2.7±3.4 kg (P<0.0001) and change in daily stool frequency of -1.0±1.3 (P<0.001). Improvements in abdominal pain, flatulence and stool consistency were observed. CONCLUSIONS Pancrelipase was well tolerated over 6 months and resulted in statistically significant weight gain and reduced stool frequency in patients with EPI due to CP or PS previously managed with standard PERT.
Collapse
|
807
|
Xia X, Lie TK, Qian X, Zheng Z, Huang Y, Shen Y. Species diversity, distribution, and genetic structure of endophytic and epiphytic Trichoderma associated with banana roots. MICROBIAL ECOLOGY 2011; 61:619-625. [PMID: 21063870 DOI: 10.1007/s00248-010-9770-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2010] [Accepted: 10/28/2010] [Indexed: 05/30/2023]
Abstract
Selective isolation, molecular identification and AFLP were used to investigate the distribution of the various species of endophytic and epiphytic Trichoderma associated with banana roots and to compare and contrast their genetic structure. Three specific groups of Trichoderma were observed in the roots of banana. Group one, which made up the largest population, comprised T. asperellum, T. virens, and Hypocrea lixii, which were isolated from both inside and on the surface of the banana roots, while group two, made up of T. atroviride and T. koningiopsis, existed on the surface only. Group three, comprising only T. brevicompactum was isolated from the inside of the roots. The AFLP analysis revealed Nei's diversity indices of 0.15 and 0.26 for epiphytic T. asperellum and T. virens, respectively. The index values of 0.11 and 0.11 were obtained for endophytic T. asperellum and T. virens, respectively. The genetic diversity within endophytic T. asperellum and T. virens was lower than that within the epiphytes. This suggests that endophytic Trichoderma has a higher genetic conservation and is compatible with the relatively stable microenvironments inside roots.
Collapse
|
808
|
Xie Y, Zhang W, Li Y, Wang M, Cerny RL, Shen Y, Du L. Transformation ofFusarium verticillioideswith a polyketide gene cluster isolated from a fungal endophyte activates the biosynthesis of fusaric acid. Mycology 2011. [DOI: 10.1080/21501203.2011.554907] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
809
|
Murata H, Malliaras GG, Uchida M, Shen Y, Kafafi ZH. Silole Derivatives with a High and Non-dispersive Electron Mobility, and a 100 % Photoluminescence Quantum Efficiency. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-665-c6.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTNon-dispersive and fast electron transport was realized for an amorphous, vapor deposited film of 2,5-bis(2',2''-bipyridin-6-yl)-1,1-dimethyl-3,4-diphenylsilacyclopentadiene in ambient and inert atmospheres. An electron mobility of 2×10−4 cm2/Vs was measured by time-of-flight at an electric field of 6×105 V/cm. This mobility is more than two orders of magnitude larger than that of the most widely used electron transporter, tris(quinolin-8-olato) aluminum (III), in molecular organic light-emitting devices (MOLEDs). Another silole derivative, namely 1,2-bis (1-methyl-2,3,4,5,-tetraphenylsilacyclopentadienyl)ethane, exhibits bright fluorescent blue-green light with an absolute quantum yield close to 100 % in the solid state. MOLEDs composed of stacked neat films of these two silole derivatives and a hole transporter show a significantly low operating voltage and an external quantum efficiency of 4.8 %, close to the theoretical limit.
Collapse
|
810
|
Zhang W, Wang M, Huang Y, Chea S, Zheng Z, Qian X, Shen Y. New and highly efficient methodology for screening high-yield strains of cytotoxic deacetylmycoepoxydiene (DAM). Lett Appl Microbiol 2011; 52:441-7. [DOI: 10.1111/j.1472-765x.2011.03015.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
811
|
Horikawa Y, Tsuchiya N, Yuasa K, Narita S, Saito M, Takayama K, Nara T, Tsuruta H, Obara T, Numakura K, Satoh S, Habuchi T, Hu X, Guo J, Lin Z, Sun L, Xu Z, Cang C, Wang G, Kanda T, Sakamoto K, Matsuki A, Ohashi R, Hirota S, Fujimori Y, Matsuda Y, Yajima K, Kosugi S, Hatakeyama K, Kitahara K, Watanabe M, Nakazono S, Wada N, Kakizaki H, Li J, Gong FJ, Sun PN, Shen L, Li Q, Li N, Qiu M, Liu J, Yi C, Luo D, Li Z, Gou H, Yang Y, Cao D, Shen Y, Wang X, Xu F, Bi F, Li Q, Zhang X, Li N, Wei W, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, He YJ, Li YH, Xu RH, Matsusaka S, Mizunuma N, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Hatake K, Nara E, Kodaira M, Mishima Y, Yokoyama M, Saotome T, Terui Y, Takahashi S, Hatake K, Nishimura N, Nakano K, Kodaira M, Ueda K, Yamada S, Mishima Y, Yokoyama M, Saotome T, Takahashi S, Terui Y, Hatake K, Nozawa M, Mochida Y, Nishigaki K, Nagae S, Uemura H, Oh SY, Jeong CY, Hong SC, Lee WS, Kim HG, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH, Ozaka M, Ogura M, Matsusaka S, Shinozaki E, Suenaga M, Chin K, Mizunuma N, Hatake K, Pua PF, Ganzon D, Chan V, Sailaja K, Vishnupriya S, Raghunadharao D, Markandeya G, Reddy PRK, Reddanna P, Praveen D, Sakamoto K, Kanda T, Matsuki A, Takano T, Hanyu T, Yajima K, Kosugi S, Hirota S, Hatakeyama K, Shigekawa T, Ijichi N, Takayama S, Tsuda H, Ikeda K, Horie K, Osaki A, Saeki T, Inoue S, Subhashini J, Rajesh B, Rajesh I, Ravindran P, Takagi K, Chin K, Oba M, Kuboki Y, Ichimura T, Oto M, Kawazoe Y, Watanabe T, Ozaka M, Ogura M, Suenaga M, Shinozaki E, Matsusaka S, Mizunuma N, Hatake K, Ueda K, Saotome T, Yamada S, Nishimura N, Nara E, Nakano K, Kodaira M, Katsube A, Mishima Y, Terui Y, Yokoyama M, Takahashi S, Hatake K, Yao X, Yang Q, Li C, Diao L, Chen X, Yu Z, Zuo W, Wang Y, He Y, Zhang X, Cai S, Wang Z, Xu J, Zhan W, Zhang YF, Misumi M, Takeuchi H, Nakamiya N, Shigekawa T, Matsuura K, Fujiuchi N, Osaki A, Saeki T. CLINICAL OUTCOMES. Jpn J Clin Oncol 2011. [DOI: 10.1093/jjco/hyq254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
812
|
Yu HE, Hawash K, Picker J, Stoler J, Urion D, Wu BL, Shen Y. A recurrent 1.71 Mb genomic imbalance at 2q13 increases the risk of developmental delay and dysmorphism. Clin Genet 2011; 81:257-64. [DOI: 10.1111/j.1399-0004.2011.01637.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
813
|
Meng Z, Liu L, Shen Y, Yang P, Cohen L, Huo Y, Zhao Q, Ng CS, Chang DZ, Garrett CR. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.284] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
284 Background: Wild toad venom has been used for over 1,000 years as a traditional Chinese medicine; H, the extract of dried toad skin glands, is a potent cardiac glycoside without significant toxicity. H has demonstrated preliminary evidence of antitumor activity in phase I clinical trial evaluation (Cancer 2009, 115:5309-18). Methods: We conducted a randomized, single-blind, phase II clinical trial of G + H versus G + placebo in patients with LAPC or MPC. Plasma bufalin levels were performed in H-treated subjects. 80 evaluable subjects accrued from October 2007 to May 2010 and were treated with G 1,000mg/m2 (iv on days 1, 8, 15, q 28d) plus either H (20 mL/m2 iv daily for 21 days followed by 7 days off, q 28d) or placebo. Demographic data is demonstrated in the table below. Results: Grade 3/4 adverse events, objective radiographic response rates (ORR), time to progression (TTP), quality of life (QOL), and overall survival (OS) were similar in the two groups (Table). There was not a statistically significant difference in the average plasma bufalin levels in patients with a radiographic partial response (PR) or stable disease versus those with progressive disease (PD) (0.098 ± 0.093 ng/mL vs. 0.071 ± 0.048 ng/mL, p=0.679). Conclusions: H when added to G was well tolerated but did not improve OS, TTP, QOL, or ORR. Further investigation of a more potent oral formulation of H is planned. H provided by Shenzhen 999 Traditional Chinese Medicine & Development Co., Ltd. Supported by NIH U19CA121503-01. [Table: see text] No significant financial relationships to disclose.
Collapse
|
814
|
Hsu C, Shen Y, Cheng C, Cheng A, Hu F, Yeh K. Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-regression approach. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
109 Background: The standard of chemotherapy regimens for patients with advanced or metastatic gastric cancer vary and the clinical outcome were heterogeneous in Asian vs. non-Asian countries. Methods: Treatment group-based meta-analysis and meta-regression were performed to analyze results of randomized trials published since 2005 for advanced or metastatic gastric cancer patients who received systemic chemotherapy as first-line treatment. Data were extracted and synthesized according to the Cochrane guidelines. Results: Among the 24 trials (totally 6,502 patients) eligible for meta-analysis, Asian trials reported lower percentage of gastroesophageal junctional carcinoma, higher percentage of diffuse-type histology, and more frequent use of second-line chemotherapy. Meta- regression analyses indicate that, after controlling other patient or treatment factors, Asian trials are associated with 22.7% (95% CI: 19.5-26.0%, p<0.0001) lower incidence of grade 3-4 neutropenia and 3.5% (95% CI: 2.1-4.9%, p<0.0001) lower incidence of grade 3-4 diarrhea, which were the most commonly reported toxicity. The use of high-dose infusional 5-fluorouracil, compared with other fuoropyrimidine regimens, reported 16.6% lower incidence of neutropenia (95% CI: 13.3-19.9%, p<0.0001). Higher percentage of patients with gastroesophageal junction carcinoma and patients with 2 or more organs involved predicted poor progression-free survival. The use of second-line chemotherapy predicts better 1-year overall survival, which will increase by 9% (95% CI: 8-10%) for every 10 percent increase in patients who received second-line chemotherapy. Conclusions: Geographic region (Asian vs. non-Asian) plays an important role in the heterogeneity of gastric cancer clinical trials and is an independent predictor of safety in systemic therapy for gastric cancer. No significant financial relationships to disclose.
Collapse
|
815
|
Yeh K, Shen Y, Li C, Yen C, Hsu C, Lin Z, Chen L, Su W, Chao Y, Cheng A. Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
86 Background: Cisplatin-HDFL, consisting of weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil (5-FU) and leucovorin (LV), is an effective and low-toxicity regimen for patients with advanced gastric cancer (GC) in Taiwan (J Clin Oncol. 1994;12(4):875; J Clin Oncol. 2006;24(18S):A14063). Everolimus (RAD001), a derivative of rapamycin, is an orally bioavailable mTOR inhibitor. We have demonstrated that low-dose everolimus (0.5-5.0 nM) sensitizes cytotoxic effects of cisplatin and 5-FU in GC cells (Proc Am Assoc Cancer Res. 2007;48:A4043). Methods: Patients who had pathologically confirmed chemonaive advanced GC, at least 1 measurable lesion, a fasting serum triglyceride level > 70 mg/dl, ECOG PS 0-2, and adequate organ functions were treated with everolimus 10 mg po on days 1, 8, and 15 concurrently with the initiation of chemotherapy; cisplatin 35 mg/m2 iv 24h infusion on days 1 and 8; 5-FU 2,000 mg/m2 and LV 300 mg/m2 (HDFL) iv 24h infusion on days 1, 8, and 15, in a every 28-day cycle. Response assessment was performed every 2 cycles. The primary endpoint was confirmed objective response rate (RR) by RECIST. Results: Between March 2008 and July 2010, 24 patients (M:11, F:13) with a median age of 53 (range: 33-69) were evaluable for response. The overall RR was 50% (95% CI: 29-71%) with 12 partial responders. Among a total of 162 cycles (median: 7, range: 1-13) given, grade (Gr) 3/4 toxicities included neutropenia (4.3%), infection (2.5%), nausea (3.1%) and vomiting (3.1%). Gr 1/2 nausea, vomiting, stomatitis, and diarrhea developed in 19.2%, 15.4%, 14.8%, and 5.5% of cycles, respectively. Skin rash and hand-foot syndrome were mild. One patient developed reversible HDFL-related hyperammonemic encephalopathy. Median progression-free survival was 8.4 months (range: 1.3-15.4+) and median overall survival was 14.8 months (range: 4.0-21.6+). Conclusions: Weekly low-dose everolimus plus weekly cisplatin-HDFL is an effective first-line regimen for patients with advanced GC. Addition of weekly low-dose everolimus to infusional cisplatin-HDFL did not add gastrointestinal toxicities. No significant financial relationships to disclose.
Collapse
|
816
|
Shen Y, Nicoletti P, Floratos A, Pirmohamed M, Molokhia M, Geppetti P, Benemei S, Giomi B, Schena D, Vultaggio A, Stern R, Daly MJ, John S, Nelson MR, Pe'er I. Genome-wide association study of serious blistering skin rash caused by drugs. THE PHARMACOGENOMICS JOURNAL 2011; 12:96-104. [PMID: 21221126 DOI: 10.1038/tpj.2010.84] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe, potentially life threatening adverse drug reactions characterized by skin blistering. Previous studies have identified drug-specific and population-specific genetic risk factors with large effects. In this study, we report the first genome-wide association study (GWAS) of SJS/TEN induced by a variety of drugs. Our aim was to identify common genetic risk factors with large effects on SJS/TEN risk. We conducted a genome-wide analysis of 96 retrospective cases and 198 controls with a panel of over one million single-nucleotide polymorphisms (SNPs). We further improved power with about 4000 additional controls from publicly available datasets. No genome-wide significant associations with SNPs or copy number variants were observed, although several genomic regions were suggested that may have a role in predisposing to drug-induced SJS/TEN. Our GWAS did not find common, highly penetrant genetic risk factors responsible for SJS/TEN events in the cases selected.
Collapse
|
817
|
Shen Y, Garnier J, Allais L, Crepin J, Ancelet O, Hiver JM. Experimental and numerical characterization of anisotropic damage evolution of forged Al6061-T6 alloy. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.proeng.2011.04.565] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
818
|
Chen C, Peng J, Shen Y, Chen D, Zhang H, Meng C. Fabrication and Characterization of Luminescent Multilayer Films Based on Polyoxometalates and Fuchsin Basic. ZEITSCHRIFT FUR NATURFORSCHUNG SECTION B-A JOURNAL OF CHEMICAL SCIENCES 2011. [DOI: 10.5560/znb.2011.66b0043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
819
|
Chen A, Shen Y, Xia M, Xu L, Pan N, Yin Y, Miao F, Shen C, Xie W, Zhang J. Expression of the nonclassical HLA class I and MICA/B molecules in human hepatocellular carcinoma. Neoplasma 2011; 58:371-6. [PMID: 21744989 DOI: 10.4149/neo_2011_05_371] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
HLA-G and HLA-E are nonclassical human MHC class I molecules, which promote tolerance to NK cytotoxicity. MICA and MICB are known to enhance the functions of NK and T cells. However, the expression of these molecules has never been investigated in liver cancer. Using RT-PCR and western blot, we aimed to identify the expression of HLA-G, HLA-E, MICA and MICB in a panel of 41 tissues dissecting from liver cancer patients in China. HLA-G mRNA was expressed in 8 of 41 Human Hepatocellular Carcinoma (HCC) specimens and in 1 adjacent normal hepatocellular tissue. The expression of HLA-G protein was found in 7 of the 8 HLA-G mRNA-positive HCC tissues. HLA-E mRNA was up-regulated in 56% HCC specimens but the expression of HLA-E protein was only upregulated in 29% HCC tissues in comparison with their adjacent normal counterpart. MICA and MICB mRNA was decreased in 5% and 8% HCC specimens, while the expression of their proteins decreased in 21% and 24% HCC tissues. These results suggested that the expressions of HLA-G, HLA-E, MICA and MICB were differently up-regulated in HCC tissues. Furthermore, HLA-E and MICA/B genes showed obviously distinctive expression pattern at transcription and translation level.
Collapse
|
820
|
Arthur JF, Shen Y, Gardiner EE, Coleman L, Murphy D, Kenny D, Andrews RK, Berndt MC. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 2011; 9:163-72. [PMID: 20946164 DOI: 10.1111/j.1538-7836.2010.04091.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND Reactive oxygen species generation is one consequence of ligand engagement of platelet glycoprotein (GP) receptors GPIb-IX-V and GPVI, which bind VWF/collagen and initiate thrombosis at arterial shear; however, the precise molecular mechanism coupling redox pathway activation to engagement of these receptors is unknown. OBJECTIVE The objective of this study was to identify novel binding partners for GPIb-IX-V and GPVI that could provide a potential link between redox pathways and early platelet signaling events. METHODS AND RESULTS Using protein array analysis and affinity-binding assays, we demonstrated that the orphan TNF receptor-associated factor (TRAF) family member, TRAF4, selectively binds cytoplasmic sequences of GPIbβ and GPVI. TRAF4, p47(phox) [of the NADPH oxidase (Nox2) enzyme complex] and other redox relevant signaling proteins such as Hic-5, co-immunoprecipitate with GPIb/GPVI from human platelet lysates whilst MBP-TRAF4 or MBP-p47(phox) fusion proteins specifically pull-down GPIb/GPVI. GPIb- or GPVI-selective agonists induce phosphorylation of the TRAF4-associated proteins, Hic-5 and Pyk2, with phosphorylation attenuated by Nox2 inhibition. CONCLUSION These results describe the first direct association of TRAF4 with a receptor, and identify a novel binding partner for GPIb-IX-V and GPVI, providing a potential link between these platelet receptors and downstream TRAF4/Nox2-dependent redox pathways.
Collapse
|
821
|
Tian Y, Yuan Z, Liu Y, Liu W, Zhang W, Xue J, Shen Y, Liang X, Chen T, Kishimoto C. Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice. Nutr Metab Cardiovasc Dis 2011; 21:25-32. [PMID: 19819680 DOI: 10.1016/j.numecd.2009.07.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2009] [Revised: 06/29/2009] [Accepted: 07/22/2009] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND AIMS Pioglitazone (PIO) affects T cell-mediated immunity through actions of peroxisome proliferator activated receptor γ (PPARγ). Effector and regulatory T cells control the development of atherosclerosis, a chronic inflammatory disease affecting the arterial blood vessels. The aim of this study was to examine whether PIO ameliorates atherosclerosis by altering the balance of effector and regulatory T cells. METHODS AND RESULTS To explore the effect of PIO on early and advanced atherosclerosis, apolipoprotein E deficient (ApoE-/-) mice were fed western diet and received PIO (20 mg/kg/day) by gastric gavage at 6 or 14 weeks of age, respectively for 8 weeks. Data showed PIO markedly inhibited early fatty streak formation. Further, although the advanced fibrofatty plaque sizes were not significantly reduced, the numbers of smooth muscle cells within lesions were increased and higher collagen concentrations were produced. In general, macrophage expression in lesions was decreased. Additionally, the expression of Foxp3(+) cells was increased in lesions and spleens in mice at all PIO treatment stages, whereas the CD4(+)IFN-γ(+)/CD4(+)IL-4(+) cell ratios were reduced. CONCLUSION PIO inhibited early atherosclerotic lesion formation and increased the stability of advanced atherosclerotic plaques in ApoE-/- mice, which was associated with altering the balance of effector and regulatory T cells.
Collapse
|
822
|
Wu Y, Kang Q, Shen Y, Su W, Bai L. Cloning and functional analysis of the naphthomycin biosynthetic gene cluster in Streptomyces sp. CS. MOLECULAR BIOSYSTEMS 2011; 7:2459-69. [DOI: 10.1039/c1mb05036b] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
823
|
Dong JZ, Shen Y, Zhang J, Tsomaia N, Mierke DF, Taylor JE. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes Obes Metab 2011; 13:19-25. [PMID: 21114599 DOI: 10.1111/j.1463-1326.2010.01313.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM Glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes are administered by daily injection because of short plasma half-lives, which result partly from the biochemical instability of these peptides. There is a medical need for GLP-1 analogues that can be administered less frequently for patient convenience. METHODS We synthesized a series of human GLP-1 (hGLP-1(7-36)NH(2) ) derivatives containing α-aminoisobutyric acid (Aib) substitutions, analysed their enzymatic stabilities and evaluated their secondary structures using circular dichroism (CD) and nuclear magnetic resonance (NMR). RESULTS Plasma stability experiments showed that only the analogue containing Aib substitutions in both the N-terminus (position 8) and the C-terminus (position 35), [Aib⁸(,)³⁵]hGLP-1(7-36)NH₂ (BIM-51077), was fully resistant to enzymatic cleavage. Incubation with human plasma kallikrein or plasmin confirmed that the Aib substitution at position 35 prevented protease cleavage around this residue, which contributes to the significantly enhanced plasma stability and increased plasma half-life. CD revealed increased C-terminal α-helicity in Aib³⁵-substituted analogues compared with both hGLP-1(7-36)NH₂ and analogues containing only Aib⁸ substitutions. Based on NMR studies, the secondary structure of BIM-51077 is similar to hGLP-1(7-36)NH₂ with a slight increase in α-helicity in the C-terminus. Compared with hGLP-1(7-36)NH₂, BIM-51077 had similar binding affinity for the human GLP-1 receptor and activated this receptor with similar potency. CONCLUSIONS We have discovered an Aib⁸(,)³⁵-substituted analogue of native hGLP-1(7-36)NH₂ (BIM-51077) that retains the structure of the native peptide, and has similar activity and enhanced stability. A sustained-release formulation of this molecule (taspoglutide) is in phase-3 clinical development.
Collapse
|
824
|
Burke D, Zhou X, Rotty V, Konchada V, Shen Y, Konety B, Sweet R. Web-accessible interactive software of 3D anatomy representing pathophysiological conditions to enhance the patient-consent process for procedures. Stud Health Technol Inform 2011; 163:96-98. [PMID: 21335769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Conveying to a patient the exact physical nature of a disease or procedure can be difficult. By establishing an access website, and using existing 3D viewer software along with our expanding set of anatomical models, we can provide an interface to manipulate realistic, 3D models of common anatomical ailments, chosen from a database frequently updated at the request of the medical community. Physicians will be able to show patients exactly what their condition looks like internally, and explain in better detail how a procedure will be performed.
Collapse
|
825
|
Lou L, Qian G, Xie Y, Hang J, Chen H, Zaleta-Rivera K, Li Y, Shen Y, Dussault PH, Liu F, Du L. Biosynthesis of HSAF, a tetramic acid-containing macrolactam from Lysobacter enzymogenes. J Am Chem Soc 2010; 133:643-5. [PMID: 21171605 DOI: 10.1021/ja105732c] [Citation(s) in RCA: 162] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
HSAF was isolated from Lysobacter enzymogenes , a bacterium used in the biological control of fungal diseases of plants. Structurally, it is a tetramic acid-containing macrolactam fused to a tricyclic system. HSAF exhibits a novel mode of action by disrupting sphingolipids important to the polarized growth of filamentous fungi. Here we describe the HSAF biosynthetic gene cluster, which contains only a single-module polyketide synthase/nonribosomal peptide synthetase (PKS/NRPS), although the biosynthesis of HSAF apparently requires two separate polyketide chains that are linked together by one amino acid (ornithine) via two amide bonds. Flanking the PKS/NRPS are six genes that encoding a cascade of four tightly clustered redox enzymes on one side and a sterol desaturase/fatty acid hydroxylase and a ferredoxin reductase on the other side. The genetic data demonstrate that the four redox genes, in addition to the PKS/NRPS gene and the sterol desaturase/fatty acid hydroxylase gene, are required for HSAF production. The biochemical data show that the adenylation domain of the NRPS specifically activates L-ornithine and that the four-domain NRPS is able to catalyze the formation of a tetramic acid-containing product from acyl-S-ACP and ornithinyl-S-NRPS. These results reveal a previously unrecognized biosynthetic mechanism for hybrid PK/NRP in prokaryotic organisms.
Collapse
|